BLAINTRAVESICALSOLUTION
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
6/8 — Strong
ANKTIVA (nogapendekin alfa inbakicept-pmln) by Immunitas Therapeutics is inbakicept-pmln is an il-15 receptor agonist. Approved for community-acquired pneumonia, acute respiratory distress syndrome, sepsis and 2 more indications. First approved in 2024.
Drug data last refreshed 21h ago
Mechanism of Action
inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared…
Worked on ANKTIVA at Immunitas Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.